The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.
Fujian Guangshengtang Pharmaceutical Co., Ltd. announced that its innovative hepatitis B treatment drug, Neracorvir, has been added to the Breakthrough Therapy List, potentially accelerating its development. This inclusion recognizes the drug's significant clinical advantages and novel antiviral mechanism, distinguishing it from existing treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.